Background
Multi-institutional, randomized, open-label phase 2 RCT. 157 patients with untreated metastatic pancreatic ductal adenocarcinoma. Tested a sequential nab-paclitaxel/gemcitabine–mFOLFOX strategy vs standard nab-paclitaxel/gemcitabine first-line.
Interventions and follow up
Arm A: nab-paclitaxel/gemcitabine on days 1, 8, 15 followed by mFOLFOX on day 29 of a 6-week cycle (alternating/sequential)
Arm B: Standard nab-paclitaxel/gemcitabine on days 1, 8, 15 of a 4-week cycle
Primary endpoint: 12-month overall survival rate
Median follow-up: NR
Arm B: Standard nab-paclitaxel/gemcitabine on days 1, 8, 15 of a 4-week cycle
Primary endpoint: 12-month overall survival rate
Median follow-up: NR
Results
12-mo OS: 55.3% (arm A) vs 35.4% (arm B); P=.02
24-mo OS: 22.4% vs 7.6%
mOS: 13.2 mo vs 9.7 mo; HR 0.68, 95% CI 0.48–0.95, P=.02
24-mo OS: 22.4% vs 7.6%
mOS: 13.2 mo vs 9.7 mo; HR 0.68, 95% CI 0.48–0.95, P=.02
Adverse events
Hematologic: Neutropenia 45.1% (arm A) vs 24.1% (arm B); thrombocytopenia 23.1% vs 7.6%
Overall: Toxicity was higher with the sequential regimen but manageable; quality of life was not compromised
Overall: Toxicity was higher with the sequential regimen but manageable; quality of life was not compromised
Conclusions
Upfront nab-paclitaxel/gemcitabine followed by mFOLFOX significantly improved 12-month and median survival versus standard nab-paclitaxel/gemcitabine in metastatic pancreatic adenocarcinoma, with increased but manageable toxicity.
Key Limitations
Modest, single-country (Spain) phase 2 sample (n=157) limits precision and generalizability. The control arm was nab-paclitaxel/gemcitabine alone rather than FOLFIRINOX, the other standard first-line option, so comparative positioning against the most active regimen is uncertain. Open-label design and absence of a reported median follow-up constrain interpretation.
Clinical Context
SEQUENCE explored an intensified, time-sequenced backbone for fit patients with metastatic pancreatic cancer. First-line standards per ESMO remain FOLFIRINOX (or NALIRIFOX) and nab-paclitaxel/gemcitabine for patients with adequate performance status; the sequential strategy is hypothesis-generating and awaits phase 3 confirmation before practice change.